Vgas Pharmaceutical

V-GAS Therapeutics is a pre-clinical stage biotechnology company dedicated to developing innovative therapies for aggressive cancers by targeting the GAS6/AXL signaling axis. The company's primary asset, VG-001, is a recombinant decoy receptor that binds with high affinity to GAS6, preventing it from activating the AXL receptor, which is known to promote tumor metastasis, survival, and resistance to therapy. Spun out of Stanford University, V-GAS focuses on indications with high unmet needs, including ovarian and pancreatic cancers. The company's approach is rooted in extensive research into the role of hypoxia and the tumor microenvironment in cancer progression. V-GAS is currently advancing its lead candidate through pre-clinical development and IND-enabling studies.